Based on our internationally recognized expertise in diabetes, obesity, pancreatic ß-cell function, and brain, we offer a complete array of preclinical services for compound testing and target validation using state-of-the-art approaches and experimental models.
Betagenex is a preclinical Contract Research Organization (CRO) providing scientific expertise and drug discovery services in metabolic diseases to the pharmaceutical and biotech industries.
- Assessment of ß-cell function
- Metabolic phenotyping
- Targeted animal models
Innovation and new products
02.08.2013New scientific publications
Two scientific publications from Pr Poitout and Pr Prentki's teams have been published regarding insulin secretion.
02.07.2013Betagenex's founders will attend the French Speaking Society of Diabetes annual congress, March 26-29, 2013, France
During this annual congress, Pr Poitout will lead a symposium on the beta-cell as a therapeutic target for type II diabetes.
+ All news